Hemophilia A and B are X-linked diseases that predominantly affect male patients. Patients can develop coagulation factor inhibitors, which exponentially increases the treatment cost. However, the prevalence of factor VIII and IX inhibitors in Saudi Arabia is unclear.This study aimed to determine the Saudi prevalence of factor VIII and IX inhibitors.This 4-year, 7-center, cross-sectional study ...

Hemophilia is an ideal condition for gene therapy because of its monogenetic character and the fact that it requires only a small amount of the expressed protein to achieve palliation. It is not infrequently diagnosed in the absence of a family history and its initial presentation can be bleeding in the neonatal period. In a neonate with clinically significant ongoing haemorrhage, where Hemophi...

Hemophilia is a rare bleeding disorder that is attributed to a defi ciency of coagulation factors VIII, IX and XI. This defi ciency leads to a tendency of moderate to severe bleeding. This disorder occurs mainly in males, who represent 97.32% of cases.1 Hemophilia A is caused by a factor VIII (FVIII) defi ciency.2 Globally it is estimated that the prevalence of hemophilia A in 2012 was 363,668 ...

Hemophilia A, one of the most common genetic bleeding disorders, is caused by various mutations in the blood coagulation factor VIII (F8) gene. Among the genotypes that result in hemophilia A, two different types of chromosomal inversions that involve a portion of the F8 gene are most frequent, accounting for almost half of all severe hemophilia A cases. In this study, we used a transcription a...

Hemophilia is a monogenic mutational disease affecting coagulation factor VIII or IX genes. The palliative treatment of choice based on the use safe and effective recombinant clotting factors. Advanced therapies will be curative, ensuring stable durable concentrations defective circulating factor. Results have so far been encouraging in terms levels times expression using mainly adeno-associate...

OBJECTIVE The objective of this study was to investigate the prevalence of HCV (hepatitis C virus) infection in hemophilia patients in Latvia and to analyze association between natural clearance of HCV and human leukocyte antigen (HLA) class II genes. MATERIAL AND METHODS From 61 hemophilic patients participating in this study, 38 were adults and 23 were pediatric patients younger than 18 yea...

BACKGROUND People with severe hemophilia A or B, X-linked bleeding disorders due to decreased blood levels of coagulants, suffer recurrent bleeding into joints and soft tissues. Before clotting factor concentrates were available, most people with severe hemophilia developed crippling musculoskeletal deformities. Clotting factor concentrate prophylaxis aims to preserve joint function by converti...

In this issue of Blood, Astermark et al have identified novel genetic markers of inhibitory antibody formation in hemophilia patients that may ultimately lead to prediction and even prevention of this severe complication of hemophilia treatment.(1)